Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597673 | 0.88 | CCR5 (0.43) | CCR5KCNH2 | |
| SCHEMBL3603896 | 0.80 | CCL5 (0.52) | CCR5KCNH2 | |
| SCHEMBL2774105 | 0.71 | RAB9A (0.50) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL2973357 | 0.71 | CASP3 (0.47) | ALDH1A1HSD17B10MEN1KMT2ACYP2C19 | |
| SCHEMBL3607309 | 0.71 | CCR5 (0.52) | CCR5KCNH2 | |
| SCHEMBL3602078 | 0.71 | CCL5 (0.53) | CCR5KCNH2 | |
| SCHEMBL1884146 | 0.70 | CASP3 (0.48) | ALDH1A1HSD17B10MEN1KMT2ACYP2C19 | |
| SCHEMBL2142237 | 0.69 | RAB9A (0.57) | ALDH1A1MEN1KMT2AMAPK1CYP2C19 | |
| SCHEMBL23384839 | 0.69 | CASP3 (0.49) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL5915646 | 0.68 | CCR5 (0.53) | CCR5KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | US | disclosed |
| US-7615555-B2 | Piperidine derivatives as modulators of chemokine receptor CCR5 | ASTRAZENECA AB (SE) | 2009-11-10 | — | — | US | disclosed |
| US-20070167442-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | US | disclosed |
| EP-1742934-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010007-A1 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | CCR5, CCR2, CXCR3 | CCR5 1/4885KCNH2 2940/4885ALDH1A1 1094/4885 |
| US-20070167442-A1 | Chemical compounds | CCR5, CXCR3, CX3CR1 | CCR5 1/4885KCNH2 3461/4885ALDH1A1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.